HER2-Mutant NSCLC: Expert Virtual Tumor Board & NCCN Updates

A new standard of care is here for HER2-mutant advanced NSCLC. Driven by the NCCN 2026 guideline updates and striking new clinical data, our expert multidisciplinary panel explores how to seamlessly integrate frontline precision medicine into the community oncology setting. IMPORTANT #FDA UPDATE Since the recording of this activity, the #fda expanded the indication for zongertinib to adult patients with unresectable or metastatic NSCLC whose tumors have HER2 (ERBB2) tyrosine kinase domain activating mutations. This expanded approval makes zongertinib the first oral HER2 inhibitor to move into the frontline setting, marking a significant milestone in the treatment of HER2-mutant NSCLC. Complete the activity and claim CME/NCPD/CPE/AAPA credit today: https://bit.ly/3YLEtyJ View and download the slide deck here: https://bit.ly/4fGet1t 0:00 – Introduction 0:55 – Epidemiology and disease burden 1:50 – Pathology in lung cancer 2:47 – Surgical pathology vs cytopathology 3:44 – HER2 alterations in NSCLC 10:47 – Pathology best practices in NSCLC 12:11 – Reflex testing 15:27 – Current treatment of HER2-mutant NSCLC 17:34 – Case study 1: Ms. EG 22:35 – The ERBB family of receptor tyrosine kinases 23:30 - Blocking the HER2 pathway 24:40 – ADCs in HER2-mutated NSCLC 26:32 – DESTINY-Lung 02 29:40 – DESTINY-Lung01 32:31 – T-DXd toxicity 32:53 – Beamion LUNG-1 35:29 – Case Study 2 37:03 – Interstitial lung disease and ADCs 38:50 – ILD pathology 40:19 – Rates of pneumonitis with T-DXd 43:06 – Drug-Related ILD 49:22 – Managing symptoms with T-DXd 50:56 – Zongertinib 52:14 – Practical interprofessional collaboration 52:39 – Biomarker testing rates in NSCLC 54:22 – Barriers to biomarker testing in NSCLC 58:36 – Liquid biopsy 59:33 – Key Takeaways Follow us here: Facebook   / i3health   Instagram   / i3health   X   / i3health   STATEMENT OF NEED Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of ‪@coloradocancercenter‬ ; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of ‪@pennmedicine‬; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at ‪@MountSinaiNYC‬, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES Tejas Patil, MD, discloses that he has served on an advisory board or panel for AADI Bioscience, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Caris, Cellworks, Daiichi Sankyo, Foundation Medicine, Galvanize, Guardant Health, Gilead, Guidepoint, Johnson & Johnson, Jazz Pharmaceuticals, Merus, Natera, Nuvation, Pfizer, Regeneron, Rigel, Roche/Genentech, Summit Therapeutics, and Takeda; that he has served as a consultant for Boehringer Ingelheim and Johnson & Johnson; and that he has received grants/research support from Gilead and Johnson & Johnson. Beth Sandy, MSN, CRNP, FAPO, discloses that she has served on an advisory board or panel for Pfizer; that she has served on a speaker's bureau for Amgen, AstraZeneca, Janssen, Jazz, Lilly, and Merck; and that she has served as a consultant for Catalyst. Maureen F. Zakowski, MD, JD, has no relevant financial relationships to disclose. This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc. #cancertreatment #treatment #oncologyeducation #oncology #cancerpatients #lungcancer #lunghealth #lung #cme #her2 #nsclc #HER2MutantNSCLC #BiomarkerTesting #PrecisionOncology #MolecularDiagnostics #NGS #IHC #TargetedTherapy #ThoracicOncology #CME #CancerCare #Oncologist #LungCancerAwareness